These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. COVID-19 and its implications for thrombosis and anticoagulation. Connors JM; Levy JH Blood; 2020 Jun; 135(23):2033-2040. PubMed ID: 32339221 [TBL] [Abstract][Full Text] [Related]
4. Coagulation abnormalities and thrombosis in patients with COVID-19. Levi M; Thachil J; Iba T; Levy JH Lancet Haematol; 2020 Jun; 7(6):e438-e440. PubMed ID: 32407672 [No Abstract] [Full Text] [Related]
5. Coagulopathy in COVID-19. Iba T; Levy JH; Levi M; Thachil J J Thromb Haemost; 2020 Sep; 18(9):2103-2109. PubMed ID: 32558075 [TBL] [Abstract][Full Text] [Related]
6. COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation. Miesbach W; Makris M Clin Appl Thromb Hemost; 2020; 26():1076029620938149. PubMed ID: 32677459 [TBL] [Abstract][Full Text] [Related]
7. Systematic review of the prognostic utility of D-dimer, disseminated intravascular coagulation, and anticoagulant therapy in COVID-19 critically ill patients. Moreno G; Carbonell R; Bodí M; Rodríguez A Med Intensiva (Engl Ed); 2021; 45(1):42-55. PubMed ID: 32646669 [TBL] [Abstract][Full Text] [Related]
8. COVID-19-associated coagulopathy and disseminated intravascular coagulation. Asakura H; Ogawa H Int J Hematol; 2021 Jan; 113(1):45-57. PubMed ID: 33161508 [TBL] [Abstract][Full Text] [Related]
9. Thrombocytopenia and thrombosis in hospitalized patients with COVID-19. Mei H; Luo L; Hu Y J Hematol Oncol; 2020 Dec; 13(1):161. PubMed ID: 33261634 [TBL] [Abstract][Full Text] [Related]
10. How to recognize and manage COVID-19-associated coagulopathy. Gerber GF; Chaturvedi S Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):614-620. PubMed ID: 34889412 [TBL] [Abstract][Full Text] [Related]
14. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial. Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765 [TBL] [Abstract][Full Text] [Related]
15. Haematological manifestations of COVID-19: From cytopenia to coagulopathy. Agbuduwe C; Basu S Eur J Haematol; 2020 Nov; 105(5):540-546. PubMed ID: 32663356 [TBL] [Abstract][Full Text] [Related]
16. Proposal of a two-step process for the diagnosis of sepsis-induced disseminated intravascular coagulation. Iba T; Levy JH; Yamakawa K; Thachil J; Warkentin TE; Levi M; J Thromb Haemost; 2019 Aug; 17(8):1265-1268. PubMed ID: 31099127 [No Abstract] [Full Text] [Related]
17. Pathomechanisms Underlying Hypoxemia in Two COVID-19-Associated Acute Respiratory Distress Syndrome Phenotypes: Insights From Thrombosis and Hemostasis. Gando S; Wada T Shock; 2022 Jan; 57(1):1-6. PubMed ID: 34172612 [TBL] [Abstract][Full Text] [Related]
18. Coagulopathy and Plausible Benefits of Anticoagulation Among COVID-19 Patients. Ahmed SI; Khan S Curr Probl Cardiol; 2020 Sep; 45(9):100648. PubMed ID: 32703535 [TBL] [Abstract][Full Text] [Related]
19. Inflammation/coagulopathy/fibrinolysis: Dynamic indicators of COVID-19 progression in patients with moderate COVID-19 in Wenzhou, China. An H; Zhang J; Zhou T; Li T; Li S; Huang C; Chen C; Ying B; Xu Z; Jin S; Li X; Li M Clin Immunol; 2021 Nov; 232():108852. PubMed ID: 34520860 [TBL] [Abstract][Full Text] [Related]
20. Major coagulation disorders and parameters in COVID-19 patients. Teimury A; Khameneh MT; Khaledi EM Eur J Med Res; 2022 Feb; 27(1):25. PubMed ID: 35168674 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]